45 results about "Fetal protein" patented technology

The invention discloses a preparation method of an unlabelled photoelectrochemical alpha fetoprotein immunosensor, and belongs to the fields of novel nano functional materials and biosensors. On the basis of a titanium dioxide nano particle base, a trimetal alloy nano material in a dendrite nanorod form is prepared by a photoelectrochemical synthetic method, so that the prepared unlabelled photoelectrochemical alpha fetoprotein immunosensor for detecting alpha fetal protein is low in cost, high in sensitivity, good in specificity, fast in detection and simple to prepare.

The invention relates to the field of biological detection, and particularly relates to a detection kit for quantitatively detecting AFP (alpha fetal protein) and a preparation method and use of the detection kit. The invention provides a detection kit for quantitatively detecting AFP. The detection kit comprises a test paper card, wherein the test paper card comprises a bottom plate, and a sample pad, a gold-marking pad, a nitrocellulose membrane and an absorbent pad which are arranged on the surface of the bottom plate and are sequentially arranged from the loading end; the gold-marking pad comprises an AFP antibody; the nitrocellulose membrane is coated with a detection line and a quality control line; and the AFP antibody on the gold-marking pad is marked by virtue of fluorescent microspheres. The detection kit for quantitatively detecting the AFP, provided by the invention, is used for detecting the AFP through a fluorescent microsphere immune chromatography technology for the first time, has sensitivity and specificity, and has the advantages of being rapid and easy to operate, accurate in result, economical, applicable and the like.

The invention relates to a method for detecting alpha-fetal protein on the basis of an RGO-CS-Fc/Au NPs nano composite material and aptamers. According to the method, the surface of a silk-screen printing electrode is modified with RGO-CS-Fc/Au NPs by means of an electro-deposition technology and an electrostatic adsorption effect; AFP aptamers are loaded on the surface of the RGO-CS-Fc/Au NPs bymeans of a nanotechnology and an intermolecular force, and the aptamers exist on the surface of the composite material in the form of single-chain structures due to the unstable spatial structures ofthe aptamers; after AFP is added into the surface of the electrode, the AFP can be specifically combined with the AFP aptamers, so that stable spatial structures can be generated, and therefore, the AFP and the aptamers can be orderly arranged on the surface of the electrode; a current value is detected through a DPV method, a relation curve of current and the concentration of the alpha-alpha protein is depicted; and therefore, the quantitative detection of the alpha-alpha protein is realized. The method has the advantages of simple operation, time-saving performance, low cost and low detection limit.

The invention discloses an application of DDK1 as a diagnostic marker. Through analysis of a large amount of hepatocellular carcinoma samples, the inventor analyzes the expressions of DKK1 and AFP, firstly discovers that serum DKK1 has a high sensitivity and specificity on diagnosis of hepatocellular carcinoma, especially diagnosis of alpha fetal protein negative hepatocellular carcinoma, identification of hepatocellular carcinoma and alpha fetal protein positive chronic liver disease, and/or diagnosis of hepatocellular carcinoma in the early stage or small hepatocellular carcinoma, and more especially the precision of clinical diagnosis can be largely increased by DKK1-AFP combined diagnosis.

The invention discloses a combined general check protein chip for early-stage cancers mainly comprising lung cancer and belongs to the technical field of a protein chip. The combined general check protein chip for the early-stage cancers mainly comprising the lung cancer, provided by the invention, comprises a chip substrate and marker antibodies distributed on the chip substrate, wherein the chip substrate is an FAST protein chip substrate having a three-dimensional nitrocellulose basic material; one or more sample application module is arranged on the FAST protein chip substrate; the following marker antibodies are fixed on the sample application module: 14-3-3 theta, LAMR-1, TSGF (Tumor Specific Growth Factor), CEA (Cancer Embryo Antigen), SCC (Squamous Cell Carcinoma), CYFRA21-1 and positive control; the following marker antibodies are also fixed: AFP (Alpha Fetal Protein), CA242, MG-Ag, CA199, TPA (Tissue Polypeptide Antigen) and EA-IgA; and the following marker antibodies are further fixed: CA125, CA153, SF (Serum Ferritin) and PSA (Prostate Specific Antigen). According to the combined general check protein chip provided by the invention, the related indexes are highly integrated; the combined general check protein chip has the advantages of excellent stability, strong specificity, long retention period, high sensitivity, excellent repeatability, convenience in operation and low cost; the labor efficiency is increased; and a cancer patient is diagnosed and treated from the general check before clinical symptoms occur.

The invention provides a kit for detecting an alpha fetal protein. The kit is operated based on a colloidal gold immunoturbidimetry and comprises a reagent R2, wherein the Reagent R2 is a solution which contains gold nanoparticles marked with alpha fetal protein antibodies. The kit is characterized in that the particle diameters of the contains gold nanoparticles are 62.2-79.1 nomameters; the mass ratio of the contains gold nanoparticles to the alpha fetal protein antibodies is 50:(20-60). The invention also provides a preparation method of the kit. The kit provided by the invention has the characteristics of high sensitivity, high specificity, fastness in reaction and good stability, precipitations can not be generated after reaction, a biochemical analyzer is convenient to clean and the service life of the biochemical analyzer is prolonged.

The invention relates to use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases. Specifically, the invention provides use of reagents containing an associative part of at least one specific binding AFP, an associative part of at least one specific binding GP73 and an associative part of at least one specific binding CECAM1 protein in preparation of kits for diagnosis and/or prognosis of the liver diseases.

The invention relates to an alpha fetal protein (AFP) kit based on an aptamer fluorescent probe, further relates to a method for measuring AFP concentration and reagent composition and components, and belongs to the technical field of medical detection and measurement. The kit mainly comprises the components of red blood cell lysis buffer, a phosphate buffer solution (PBS), an AFP standard and the AFP aptamer fluorescent probe. The AFP concentration is measured through blood sample splitting and mixed egg cultivation in conjunction with a fluorescent spectrophotometer. The alpha fetal protein kit has the advantages of simple sample treatment, easiness and convenience in operation, short detection time, high detection specificity, high flexibility, high detection result repeatability and the like.

The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.

The invention relates to a human cancer marker detection kit and a detection method. The detection kit includes microcarriers, coating antibodies and detection antibodies. There is at least one kind of microcarrier, and the microcarrier has coding information, and the coding information of microcarriers for different human cancer markers is different. Coating antibodies are used to coat microcarriers. Both the coating antibody and the detection antibody are selected from the antibodies of carcinoembryonic antigen, alpha-fetoprotein, prostate specific antigen, tumor antigen 19-9, tumor antigen 125 and tumor antigen 15-3 For at least one of the corresponding human cancer markers, the coating antibody and the detection antibody have different antigen binding sites. The detection kit can be used to detect up to six human cancer markers, thereby enriching the detection results and assisting clinical diagnosis more effectively.

The invention discloses a human serum AFP (Alpha Fetal Protein) negative liver cell cancer detection kit. A combined diagnosis kit is used for combined diagnosis on patients suffering from AFP negative hepatocellular carcinoma by detecting expression amounts of five RNAs (Ribonucleic Acids) of MiR-125b, MiR-205, SPRY4-IT1, GAS5-AS1 and circSMARCA5 in plasma by using a real-time quantitative PCR (Polymerase Chain Reaction) technique. The kit disclosed by the invention has the characteristics of high sensitivity, high specificity and high accuracy, patients suffering from AFP negative hepatocellular carcinoma can be effectively diagnosed, auxiliary diagnosis on early-stage hepatocellular carcinoma can be achieved, the survival rate of the patients can be increased, and the kit has remarkableclinical application values.